United Therapeutics Corp

UTHRNASDAQ • USD
591.17 USD
↘ 2.14 (0.36%)AT CLOSE (03:59 PM EST)
591.25
↗ 0.08 (0.01%)
POST MARKET (AS OF 04:14 PM EST)
Post Market
AS OF 04:14 PM EST
591.25
↗ 0.08 (0.01%)
🔴Market: CLOSED

Shares of United Therapeutics Corp (UTHR) are trading at $591.17. The technical outlook is "Buy" and the fundamental picture shows "Neutral". This is driven by a robust Altman Z-Score, a bullish Golden Cross on the moving averages and bullish moving average alignment. On valuation, UTHR trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Nov 13, 2026.

Open?$593.31
High?$598.84
Low?$587.00
Prev. Close?$593.31
Volume?463.5K
Avg. Volume?636.2K
VWAP?$593.65
Rel. Volume?0.73x
Bid / Ask
Bid?$550.00 × 40
Ask?$623.00 × 240
Spread?$73.00
Midpoint?$586.50
Valuation & Ratios
Market Cap?25.2B
Shares Out?42.6M
Float?42.0M
Float %?97.8%
P/E Ratio?20.46
P/B Ratio?4.01
EPS?$28.90
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
Employees
1.4K
Market Cap
25.2B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
1999-06-17
Address
1000 SPRING ST
SILVER SPRING, MD 20910
Phone: (301) 608-9292
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
40
Z-Score?
100
Momentum?
35
Short Sent.?
79
Piotroski F-Score?4/9Mixed
Altman Z-Score?23.26Safe
Confidence?64%Moderate
Full Fundamental Analysis →
Short InterestModerate
Short % of Float?4.38%Low
Short Interest?1.8M
Days to Cover?3.5
Free Float42.0M
Avg Daily Volume532.2K
Settlement Date2026-10-30
Financial Health
Current Ratio?4.61Strong
Quick Ratio?4.29Strong
Cash Ratio?1.90Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
56/100
P/E?
Peers
100
S&P
63
20.5FAIR▾
P/B?
Peers
100
S&P
44
4.01FAIR▾
P/S?
Peers
100
S&P
13
7.90HIGH▾
P/FCF?
Peers
100
S&P
31
29.0FAIR▾
EV/EBITDA?
Peers
100
S&P
38
16.9FAIR▾
EV/Sales?
Peers
100
S&P
18
7.53HIGH▾
Returns & Efficiency
ROE?
Peers
50
S&P
65
19.6%STRONG▾
ROA?
Peers
50
S&P
92
17.5%STRONG▾
Cash Flow & Enterprise
FCF?$867.2M
Enterprise Value?$24.0B
Fundamentals ratios updated end of day